- The USPTO issues patent no. 8,618,277 to Alnylam (ALNY +1.3%) in its McSwiggen patent estate, which broadly describes chemical modifications of RNAi therapeutics needed to achieve drug-like properties in siRNA. The 277 patent includes important claims related to the development of RNAi therapeutics for the treatment of hepatitis B infection. It is exclusive to the company.
- The McSwiggen patent estate includes 23 granted patents around the world and is a core component of Alnylam's IP portfolio for the advancement of RNAi therapeutics. It obtained the estate via its acquisition of Sirna Therapeutics from Merck (MRK -1%).
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Jan 23, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 12, 2015)
at Nasdaq.com (Dec 24, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs